2614 PUBLICATIONS
ANNÉE
JOURNAL
PREMIER AUTEUR
TITRE
ANNÉE2022
JOURNALMolecular oncology
PREMIER AUTEURGiolito MV
TITRERegulation of the THRA gene, encoding the thyroid hormone nuclear receptor TRα1, in intestinal lesions.
ANNÉE2022
JOURNALMolecules (Basel, Switzerland)
PREMIER AUTEURLatgé A
TITRECuCl PET Imaging of 4T1-Related Allograft of Triple-Negative Breast Cancer in Mice.
ANNÉE2022
JOURNALAdvances in radiation oncology
PREMIER AUTEURPêtre A
TITRESalvage Involved-Field and Extended-Field Radiation Therapy in Positron Emission Tomography-Positive Nodal Recurrent Prostate Cancer: Outcomes and Patterns of Failure.
ANNÉE2022
JOURNALBiomaterials science
PREMIER AUTEURNifontova G
TITREStructure-function relationships in polymeric multilayer capsules designed for cancer drug delivery.
ANNÉE2022
JOURNALJournal of the European Academy of Dermatology and Venereology : JEADV
PREMIER AUTEURMalouf GG
TITREGenetic landscape of indolent and aggressive Kaposi sarcomas.
ANNÉE2022
JOURNALAnnals of surgical oncology
PREMIER AUTEURDelhorme JB
TITREPeritoneal Metastases of Colorectal Origin Treated with Complete Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy: The Efficiency of Mitomycin C.
ANNÉE2022
JOURNALAnnals of surgical oncology
PREMIER AUTEURDelhorme JB
TITREASO Visual Abstract: Peritoneal Metastases of Colorectal Origin Treated with Complete Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy-The Efficiency of Mitomycin C.
ANNÉE2022
JOURNALClinical genitourinary cancer
PREMIER AUTEUREscudier B
TITREManagement and Health Resource Use of Patients With Metastatic Renal Cell Carcinoma treated With Systemic Therapy Over 2014-2017 in France: A National Real-World Study.
ANNÉE2022
JOURNALJournal of plastic, reconstructive & aesthetic surgery : JPRAS
PREMIER AUTEURFauconnier MB
TITREComparison of postoperative complications following conventional latissimus dorsi flap versus muscle-sparing latissimus dorsi flap breast reconstruction.
ANNÉE2022
JOURNALJournal of clinical oncology : official journal of the American Society of Clinical Oncology
PREMIER AUTEURFornecker LM
TITREBrentuximab Vedotin Plus AVD for First-Line Treatment of Early-Stage Unfavorable Hodgkin Lymphoma (BREACH): A Multicenter, Open-Label, Randomized, Phase II Trial.

Retrouvez aussi

Personnes
Equipes
Plateformes
Unités de recherche, établissements
Projets de recherche
Publications scientifiques